{"transactions":[{"id":704273,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":29060,"kind":"person","name":"Fein Seymour Howard","position":1,"cik":"0002147180","reported_name":"Fein Seymour Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CRO/CMO"}}],"security":"Restricted stock Units","published_at":"2026-07-23T20:00:18.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 10, 2026, the reporting person was granted 250 restricted stock units (\"RSUs\"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."}],"balance_after":250,"derivative":{"exercise_price":0,"underlying":"Series A Preferred Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001493152-26-034397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226034397/ownership.xml","form_type":"4"}},{"id":705373,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock Units","published_at":"2026-07-21T20:00:30.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 10, 2026, the reporting person was granted 250 restricted stock units (\"RSUs\"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."}],"balance_after":250,"derivative":{"exercise_price":0,"underlying":"Series A Preferred Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001493152-26-034069","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226034069/ownership.xml","form_type":"4"}},{"id":710123,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30643,"kind":"person","name":"MAIDA ANTHONY E III","position":1,"cik":"0001273213","reported_name":"MAIDA ANTHONY E III","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"DIRECTOR AND CMO - TRANS. MED."}}],"security":"Restricted stock Units","published_at":"2026-07-14T20:00:23.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 10, 2026, the reporting person was granted 1,500 restricted stock units (\"RSUs\"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."}],"balance_after":1500,"derivative":{"exercise_price":0,"underlying":"Series A Preferred Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001493152-26-033169","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226033169/ownership.xml","form_type":"4"}},{"id":710121,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBO"}}],"security":"Restricted stock Units","published_at":"2026-07-14T20:00:22.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 10, 2026, the reporting person was granted 1,500 restricted stock units (\"RSUs\"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."}],"balance_after":1500,"derivative":{"exercise_price":0,"underlying":"Series A Preferred Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001493152-26-033168","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226033168/ownership.xml","form_type":"4"}},{"id":710122,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted stock Units","published_at":"2026-07-14T20:00:20.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 10, 2026, the reporting person was granted 1,500 restricted stock units (\"RSUs\"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."}],"balance_after":1500,"derivative":{"exercise_price":0,"underlying":"Series A Preferred Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001493152-26-033167","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226033167/ownership.xml","form_type":"4"}},{"id":710120,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Restricted stock Units","published_at":"2026-07-14T20:00:19.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 10, 2026, the reporting person was granted 2,000 restricted stock units (\"RSUs\"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."}],"balance_after":2000,"derivative":{"exercise_price":0,"underlying":"Series A Preferred Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001493152-26-033166","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226033166/ownership.xml","form_type":"4"}},{"id":719579,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-07-02T19:00:27.000Z","date":"2026-07-01","kind":"purchase","planned":false,"acquired":true,"shares":240000,"price":0.0431,"value":10344.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On July 1, 2026, Dr. Vuong Trieu purchased 240,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0431."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On July 1, 2026, Dr. Vuong Trieu purchased 240,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0431."}],"balance_after":94124319,"source":{"system":"sec-edgar","filing":"0001493152-26-031846","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226031846/ownership.xml","form_type":"4"}},{"id":728177,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-06-25T00:37:38.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":65000,"price":0.045,"value":2925.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."}],"balance_after":93694319,"source":{"system":"sec-edgar","filing":"0001493152-26-029997","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029997/ownership.xml","form_type":"4"}},{"id":728176,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-06-25T00:37:38.000Z","date":"2026-06-23","kind":"purchase","planned":false,"acquired":true,"shares":75000,"price":0.045,"value":3375.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."}],"balance_after":93769319,"source":{"system":"sec-edgar","filing":"0001493152-26-029997","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029997/ownership.xml","form_type":"4"}},{"id":728175,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-06-25T00:37:38.000Z","date":"2026-06-24","kind":"purchase","planned":false,"acquired":true,"shares":115000,"price":0.045,"value":5175.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."}],"balance_after":93884319,"source":{"system":"sec-edgar","filing":"0001493152-26-029997","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029997/ownership.xml","form_type":"4"}},{"id":731126,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2026-06-22T20:30:18.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.05,"value":1000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On June 22, 2026, Amit Shah purchased 20,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On June 22, 2026, Amit Shah purchased 20,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05."}],"balance_after":378837,"source":{"system":"sec-edgar","filing":"0001493152-26-029594","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029594/ownership.xml","form_type":"4"}},{"id":735083,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-06-17T23:34:05.000Z","date":"2026-06-15","kind":"purchase","planned":false,"acquired":true,"shares":96000,"price":0.045,"value":4320.0,"ownership":{"direct":true},"balance_after":93389560,"source":{"system":"sec-edgar","filing":"0001493152-26-029137","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029137/ownership.xml","form_type":"4"}},{"id":735082,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-06-17T23:34:05.000Z","date":"2026-06-17","kind":"purchase","planned":false,"acquired":true,"shares":239759,"price":0.0446,"value":10693.2514,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On June 15, 2026, Dr. Vuong Trieu purchased 96,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05. Further, on June 17, 2026, Dr. Vuong Trieu purchased 239,759 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0446."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On June 15, 2026, Dr. Vuong Trieu purchased 96,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05. Further, on June 17, 2026, Dr. Vuong Trieu purchased 239,759 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0446."}],"balance_after":93629319,"source":{"system":"sec-edgar","filing":"0001493152-26-029137","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029137/ownership.xml","form_type":"4"}},{"id":931520,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2026-01-26T22:15:27.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":4426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated January 21, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."}],"balance_after":8491,"derivative":{"underlying":"Common Stock","underlying_shares":4426000},"source":{"system":"sec-edgar","filing":"0001493152-26-003634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226003634/ownership.xml","form_type":"4"}},{"id":994570,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-11-19T20:45:27.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":4065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated November 17, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."}],"balance_after":4065,"derivative":{"underlying":"Com-mon Stock","underlying_shares":4065000},"source":{"system":"sec-edgar","filing":"0001493152-25-024236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315225024236/ownership.xml","form_type":"4"}},{"id":1089717,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-07-10T21:15:14.000Z","date":"2025-07-08","kind":"purchase","planned":false,"acquired":true,"shares":94736,"price":0.005,"value":473.68,"ownership":{"direct":true},"balance_after":93388297,"source":{"system":"sec-edgar","filing":"0001641172-25-018620","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000164117225018620/ownership.xml","form_type":"4"}},{"id":1089716,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-07-10T21:15:14.000Z","date":"2025-07-09","kind":"purchase","planned":false,"acquired":true,"shares":1,"price":0.005,"value":0.005,"ownership":{"direct":true},"balance_after":93293561,"source":{"system":"sec-edgar","filing":"0001641172-25-018620","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000164117225018620/ownership.xml","form_type":"4"}},{"id":1089715,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-07-10T21:15:14.000Z","date":"2025-07-10","kind":"purchase","planned":false,"acquired":true,"shares":104000,"price":0.005,"value":520.0,"ownership":{"direct":true},"balance_after":93293560,"source":{"system":"sec-edgar","filing":"0001641172-25-018620","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000164117225018620/ownership.xml","form_type":"4"}},{"id":1290020,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-01-31T22:08:22.000Z","date":"2025-01-31","kind":"purchase","planned":false,"acquired":true,"shares":63775,"price":0.028,"value":1785.7,"ownership":{"direct":true},"balance_after":93189560,"source":{"system":"sec-edgar","filing":"0001493152-25-004486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315225004486/ownership.xml","form_type":"4"}},{"id":1290019,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-01-31T22:08:22.000Z","date":"2025-01-30","kind":"purchase","planned":false,"acquired":true,"shares":100003,"price":0.028,"value":2800.084,"ownership":{"direct":true},"balance_after":93125785,"source":{"system":"sec-edgar","filing":"0001493152-25-004486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315225004486/ownership.xml","form_type":"4"}},{"id":1290018,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-01-31T22:08:22.000Z","date":"2025-01-29","kind":"purchase","planned":false,"acquired":true,"shares":183066,"price":0.028,"value":5125.848,"ownership":{"direct":true},"balance_after":93025782,"source":{"system":"sec-edgar","filing":"0001493152-25-004486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315225004486/ownership.xml","form_type":"4"}},{"id":1351625,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2024-11-26T16:33:58.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":298499,"price":0.0289,"value":8626.6211,"ownership":{"direct":true},"balance_after":92842716,"source":{"system":"sec-edgar","filing":"0001493152-24-047762","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315224047762/ownership.xml","form_type":"4"}},{"id":1422441,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2024-08-27T12:00:06.000Z","date":"2024-08-23","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":0.02,"value":10000.0,"ownership":{"direct":true},"balance_after":92544217,"source":{"system":"sec-edgar","filing":"0001493152-24-033939","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315224033939/ownership.xml","form_type":"4"}},{"id":1841451,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-06-30T13:25:05.000Z","date":"2023-06-28","kind":"purchase","planned":false,"acquired":true,"shares":75000,"price":0.026,"value":1950.0,"ownership":{"direct":true},"balance_after":91619217,"source":{"system":"sec-edgar","filing":"0001493152-23-023015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223023015/ownership.xml","form_type":"4"}},{"id":1841450,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-06-30T13:25:05.000Z","date":"2023-06-29","kind":"purchase","planned":false,"acquired":true,"shares":425000,"price":0.021,"value":8925.0,"ownership":{"direct":true},"balance_after":92044217,"source":{"system":"sec-edgar","filing":"0001493152-23-023015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223023015/ownership.xml","form_type":"4"}},{"id":1850528,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-06-20T16:00:06.000Z","date":"2023-06-16","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.026,"value":2600.0,"ownership":{"direct":true},"balance_after":91544217,"source":{"system":"sec-edgar","filing":"0001493152-23-021800","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223021800/ownership.xml","form_type":"4"}},{"id":1853229,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-06-16T16:00:08.000Z","date":"2023-06-14","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":0.0326,"value":13040.0,"ownership":{"direct":true},"balance_after":91444217,"source":{"system":"sec-edgar","filing":"0001493152-23-021563","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223021563/ownership.xml","form_type":"4"}},{"id":1873833,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-05-31T13:39:02.000Z","date":"2023-05-26","kind":"purchase","planned":false,"acquired":true,"shares":126888,"price":0.0341,"value":4326.8808,"ownership":{"direct":true},"balance_after":91044217,"source":{"system":"sec-edgar","filing":"0001493152-23-019557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223019557/ownership.xml","form_type":"4"}},{"id":1909118,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-05-02T21:00:46.000Z","date":"2023-05-02","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.045,"value":4500.0,"ownership":{"direct":true},"balance_after":90917329,"source":{"system":"sec-edgar","filing":"0001493152-23-015195","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223015195/ownership.xml","form_type":"4"}},{"id":2093836,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2022-12-07T13:00:32.000Z","date":"2022-12-06","kind":"purchase","acquired":true,"shares":120000,"price":0.05,"value":6000.0,"ownership":{"direct":true},"balance_after":90558021,"source":{"system":"sec-edgar","filing":"0001493152-22-034663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315222034663/ownership.xml","form_type":"4"}},{"id":2104607,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2022-11-25T14:00:38.000Z","date":"2022-11-22","kind":"purchase","acquired":true,"shares":70000,"price":0.08,"value":5600.0,"ownership":{"direct":true},"balance_after":90438021,"source":{"system":"sec-edgar","filing":"0001493152-22-033681","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315222033681/ownership.xml","form_type":"4"}},{"id":2150132,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2022-09-28T13:15:09.000Z","date":"2022-09-26","kind":"purchase","acquired":true,"shares":20000,"price":0.068,"value":1360.0,"ownership":{"direct":true},"balance_after":90368021,"source":{"system":"sec-edgar","filing":"0001493152-22-026963","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315222026963/ownership.xml","form_type":"4"}},{"id":2172227,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2022-08-29T13:15:14.000Z","date":"2022-08-25","kind":"purchase","acquired":true,"shares":80000,"price":0.082,"value":6560.0,"ownership":{"direct":true},"balance_after":90348021,"source":{"system":"sec-edgar","filing":"0001493152-22-024234","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315222024234/ownership.xml","form_type":"4"}},{"id":2576521,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2021-09-08T21:00:55.000Z","date":"2021-09-03","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest as follows: (i) 1/5th on September 30, 2021; (ii) 1/5th on December 31, 2021; (iii) 1/5th on March 31, 2022; (iv) 1/5th on June 30, 2022; and (v) 1/5th on September 30, 2022."}],"balance_after":225000,"derivative":{"exercise_price":0.1393,"expiration_date":"2031-09-03","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001493152-21-022220","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221022220/ownership.xml","form_type":"4"}},{"id":2576520,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30643,"kind":"person","name":"MAIDA ANTHONY E III","position":1,"cik":"0001273213","reported_name":"MAIDA ANTHONY E III","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Clin. Ops. Officer"}}],"security":"Stock Options","published_at":"2021-09-08T21:00:50.000Z","date":"2021-09-03","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest as follows: (i) 1/5th on September 30, 2021; (ii) 1/5th on December 31, 2021; (iii) 1/5th on March 31, 2022; (iv) 1/5th on June 30, 2022; and (v) 1/5th on September 30, 2022."}],"balance_after":600000,"derivative":{"exercise_price":0.1393,"expiration_date":"2031-09-03","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001493152-21-022219","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221022219/ownership.xml","form_type":"4"}},{"id":2576519,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-09-08T21:00:44.000Z","date":"2021-09-03","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest as follows: (i) 1/5th on September 30, 2021; (ii) 1/5th on December 31, 2021; (iii) 1/5th on March 31, 2022; (iv) 1/5th on June 30, 2022; and (v) 1/5th on September 30, 2022."}],"balance_after":500000,"derivative":{"exercise_price":0.1393,"expiration_date":"2031-09-03","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001493152-21-022218","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221022218/ownership.xml","form_type":"4"}},{"id":2576518,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Options","published_at":"2021-09-08T21:00:37.000Z","date":"2021-09-03","kind":"grant","acquired":true,"shares":675000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock Options vest as follows: (i) 50% of the options will vest upon the consummation of a qualifying joint venture agreement, licensing agreement, or acquisition transaction (a \"Corporate Transaction\"); (ii) The remaining 50% on the one-year anniversary of the consummation of a Corporate Transaction."}],"balance_after":675000,"derivative":{"exercise_price":0.1393,"expiration_date":"2031-09-03","underlying":"Common Stock","underlying_shares":675000},"source":{"system":"sec-edgar","filing":"0001493152-21-022217","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221022217/ownership.xml","form_type":"4"}},{"id":2632527,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30643,"kind":"person","name":"MAIDA ANTHONY E III","position":1,"cik":"0001273213","reported_name":"MAIDA ANTHONY E III","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF CLINICAL OFFICER"}}],"security":"Stock Options","published_at":"2021-07-16T21:39:03.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant."}],"balance_after":400000,"derivative":{"exercise_price":0.1626,"exercise_date":"2021-07-08","expiration_date":"2031-07-08","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001493152-21-017107","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017107/ownership.xml","form_type":"4"}},{"id":2632526,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30643,"kind":"person","name":"MAIDA ANTHONY E III","position":1,"cik":"0001273213","reported_name":"MAIDA ANTHONY E III","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF CLINICAL OFFICER"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-07-16T21:39:03.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":938,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of the Series A Convertible Preferred Stock does not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":938646},"source":{"system":"sec-edgar","filing":"0001493152-21-017107","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017107/ownership.xml","form_type":"4"}},{"id":2632525,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30643,"kind":"person","name":"MAIDA ANTHONY E III","position":1,"cik":"0001273213","reported_name":"MAIDA ANTHONY E III","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF CLINICAL OFFICER"}}],"security":"Common Stock","published_at":"2021-07-16T21:39:03.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":938646,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."}],"balance_after":1137314,"source":{"system":"sec-edgar","filing":"0001493152-21-017107","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017107/ownership.xml","form_type":"4"}},{"id":2632524,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Options","published_at":"2021-07-16T21:38:27.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":513953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan and which vest immediately on the date of grant."}],"balance_after":513953,"derivative":{"exercise_price":0.1626,"exercise_date":"2021-07-08","expiration_date":"2031-07-08","underlying":"Common Stock","underlying_shares":513953},"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632523,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":5672,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of the Series A Convertible Preferred Stock does not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5672025},"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632522,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":13849,"ownership":{"direct":false,"nature":"By Autotelic, Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of the Series A Convertible Preferred Stock does not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13849161},"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632521,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":74456,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of the Series A Convertible Preferred Stock does not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":74455719},"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632520,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":5672025,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."}],"balance_after":6872529,"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632519,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":13849161,"ownership":{"direct":false,"nature":"By Autotelic, Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."}],"balance_after":16780384,"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632518,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":259302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant."}],"balance_after":90527323,"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632517,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":74455719,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."}],"balance_after":90268021,"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632516,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-07-16T21:37:41.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":357412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vests immediately on the date of grant."}],"balance_after":357412,"derivative":{"exercise_price":0.1626,"exercise_date":"2021-07-08","expiration_date":"2031-07-08","underlying":"Common Stock","underlying_shares":357412},"source":{"system":"sec-edgar","filing":"0001493152-21-017105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017105/ownership.xml","form_type":"4"}},{"id":2632515,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-07-16T21:37:41.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":3292,"ownership":{"direct":false,"nature":"By Artius Bioconsulting"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of the Series A Convertible Preferred Stock does not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3291720},"source":{"system":"sec-edgar","filing":"0001493152-21-017105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017105/ownership.xml","form_type":"4"}},{"id":2632514,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":29367,"kind":"person","name":"KING STEVEN W","position":1,"cik":"0001244106","reported_name":"KING STEVEN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-16T21:37:41.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":3291720,"ownership":{"direct":false,"nature":"By Artius Bioconsulting"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."}],"balance_after":3330647,"source":{"system":"sec-edgar","filing":"0001493152-21-017105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017105/ownership.xml","form_type":"4"}},{"id":2632513,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Options","published_at":"2021-07-16T21:37:37.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":698256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on date of grant."}],"balance_after":698256,"derivative":{"exercise_price":0.1626,"exercise_date":"2021-07-08","expiration_date":"2031-07-08","underlying":"Common Stock","underlying_shares":698256},"source":{"system":"sec-edgar","filing":"0001493152-21-017104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017104/ownership.xml","form_type":"4"}},{"id":2632512,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2021-07-16T21:37:37.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":298837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant."}],"balance_after":358837,"source":{"system":"sec-edgar","filing":"0001493152-21-017104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017104/ownership.xml","form_type":"4"}},{"id":2632571,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":109313,"kind":"person","name":"Diamond David","position":1,"cik":"0001802807","reported_name":"Diamond David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-07-16T21:36:50.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":451467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant."}],"balance_after":451467,"derivative":{"exercise_price":0.1626,"exercise_date":"2021-07-08","expiration_date":"2031-07-08","underlying":"Common Stock","underlying_shares":451467},"source":{"system":"sec-edgar","filing":"0001493152-21-017103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017103/ownership.xml","form_type":"4"}},{"id":2632511,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Options","published_at":"2021-07-16T21:35:47.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":216279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant."}],"balance_after":216279,"derivative":{"exercise_price":0.1626,"exercise_date":"2021-07-08","expiration_date":"2031-07-08","underlying":"Common Stock","underlying_shares":216279},"source":{"system":"sec-edgar","filing":"0001493152-21-017102","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017102/ownership.xml","form_type":"4"}},{"id":2632510,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-07-16T21:35:47.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":16355,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the \"Merger\"), shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the \"Merger\"), shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the \"Merger\"), shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of the Series A Convertible Preferred Stock does not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16354961},"source":{"system":"sec-edgar","filing":"0001493152-21-017102","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017102/ownership.xml","form_type":"4"}},{"id":2632509,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2021-07-16T21:35:47.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":102519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant."}],"balance_after":16457480,"source":{"system":"sec-edgar","filing":"0001493152-21-017102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017102/ownership.xml","form_type":"4"}},{"id":2632508,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30641,"kind":"person","name":"Saund Saran","position":1,"cik":"0001834417","reported_name":"Saund Saran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Common Stock","published_at":"2021-07-16T21:35:47.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":16354961,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the \"Merger\"), shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."}],"balance_after":16354961,"source":{"system":"sec-edgar","filing":"0001493152-21-017102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017102/ownership.xml","form_type":"4"}},{"id":2968835,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-11-24T22:30:34.000Z","date":"2020-11-24","kind":"purchase","acquired":true,"shares":8220,"price":0.19,"value":1561.8,"ownership":{"direct":true},"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001493152-20-022450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315220022450/ownership.xml","form_type":"4"}},{"id":2968834,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-11-24T22:30:34.000Z","date":"2020-11-23","kind":"purchase","acquired":true,"shares":20088,"price":0.19,"value":3816.72,"ownership":{"direct":true},"balance_after":51780,"source":{"system":"sec-edgar","filing":"0001493152-20-022450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315220022450/ownership.xml","form_type":"4"}},{"id":2968833,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-11-24T22:30:34.000Z","date":"2020-11-20","kind":"purchase","acquired":true,"shares":31692,"price":0.195,"value":6179.94,"ownership":{"direct":true},"balance_after":31692,"source":{"system":"sec-edgar","filing":"0001493152-20-022450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315220022450/ownership.xml","form_type":"4"}},{"id":2970287,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":145151,"kind":"person","name":"Park Chulho","position":1,"cik":"0001775662","reported_name":"Park Chulho","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF TECHNOLOGY OFFICER"}}],"security":"Common Stock","published_at":"2020-11-23T20:01:39.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":22173,"price":0.1848,"value":4097.5704,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.183 to $0.185 per share, inclusive. The\nholder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full\ninformation regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2833992,"source":{"system":"sec-edgar","filing":"0001493152-20-022257","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315220022257/ownership.xml","form_type":"4"}},{"id":2970288,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2020-11-23T20:01:35.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":50500,"price":0.19,"value":9595.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.186 to $0.195 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15812308,"source":{"system":"sec-edgar","filing":"0001493152-20-022256","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315220022256/ownership.xml","form_type":"4"}},{"id":3193556,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2020-03-27T21:49:56.000Z","date":"2020-03-26","kind":"purchase","acquired":true,"shares":3000,"price":0.12,"value":360.0,"ownership":{"direct":true},"balance_after":15761808,"source":{"system":"sec-edgar","filing":"0001415889-20-000880","document":"form4-03272020_020342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000141588920000880/form4-03272020_020342.xml","form_type":"4"}},{"id":3885576,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165549,"kind":"person","name":"Schwieterman William D","position":1,"cik":"0001403961","reported_name":"Schwieterman William D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-22T20:17:24.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Dr. Schwieterman was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"2015 Plan Options\" and, collectively with the 2017 Plan Options, the \"Options\"), pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan in connection with his service as President and Chief Executive Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options will vest in twelve equal monthly installments beginning one month after the date of grant."}],"balance_after":500000,"derivative":{"exercise_price":0.22,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-18-039187","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039187/doc4.xml","form_type":"4"}},{"id":3885575,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165549,"kind":"person","name":"Schwieterman William D","position":1,"cik":"0001403961","reported_name":"Schwieterman William D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-22T20:17:24.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Schwieterman was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"2017 Plan Options\"), pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as President and Chief Executive Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options will vest in twelve equal monthly installments beginning one month after the date of grant."}],"balance_after":500000,"derivative":{"exercise_price":0.22,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-18-039187","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039187/doc4.xml","form_type":"4"}},{"id":3885573,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165548,"kind":"person","name":"SANDAGE BOBBY W. JR., PHD.","position":1,"cik":"0001046352","reported_name":"SANDAGE BOBBY W. JR., PHD.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-22T20:16:23.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":258171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015  Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 20, 2019, subject to Dr. Sandage's continued service on the Board of Directors as of such date."}],"balance_after":258171,"derivative":{"exercise_price":0.22,"expiration_date":"2024-06-20","underlying":"Common Stock","underlying_shares":258171},"source":{"system":"sec-edgar","filing":"0001209191-18-039183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039183/doc4.xml","form_type":"4"}},{"id":3885571,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-22T20:15:05.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":258171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Reynolds was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 20, 2019, subject to Mr. Reynolds' continued service on the Board of Directors as of such date."}],"balance_after":258171,"derivative":{"exercise_price":0.22,"expiration_date":"2024-06-20","underlying":"Common Stock","underlying_shares":258171},"source":{"system":"sec-edgar","filing":"0001209191-18-039176","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039176/doc4.xml","form_type":"4"}},{"id":3885572,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":75587,"kind":"person","name":"Pedder Simon","position":1,"cik":"0001316736","reported_name":"Pedder Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-22T20:13:33.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":258171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Pedder was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 20, 2019, subject to Dr. Pedder's continued service on the Board of Directors as of such date."}],"balance_after":258171,"derivative":{"exercise_price":0.22,"expiration_date":"2024-06-20","underlying":"Common Stock","underlying_shares":258171},"source":{"system":"sec-edgar","filing":"0001209191-18-039172","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039172/doc4.xml","form_type":"4"}},{"id":3885570,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-22T20:12:51.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"2015 Plan Options\" and, collectively with the 2017 Plan Options, the \"Options\"), pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan in connection with his service as Chief Financial Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options will vest in twelve equal monthly installments beginning one month after the date of grant."}],"balance_after":500000,"derivative":{"exercise_price":0.22,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-18-039169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039169/doc4.xml","form_type":"4"}},{"id":3885569,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-06-22T20:12:51.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Loar was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"2017 Plan Options\"), pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options will vest in twelve equal monthly installments beginning one month after the date of grant."}],"balance_after":250000,"derivative":{"exercise_price":0.22,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-18-039169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039169/doc4.xml","form_type":"4"}},{"id":3885568,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165545,"kind":"person","name":"CHAPLIN DAVID","position":1,"cik":"0001167232","reported_name":"CHAPLIN DAVID","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-22T20:12:10.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":258171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Chaplin was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 20, 2019, subject to Dr. Chaplin's continued service on the Board of Directors as of such date."}],"balance_after":258171,"derivative":{"exercise_price":0.22,"expiration_date":"2024-06-20","underlying":"Common Stock","underlying_shares":258171},"source":{"system":"sec-edgar","filing":"0001209191-18-039167","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039167/doc4.xml","form_type":"4"}},{"id":3963505,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock B Warrants (Right to Buy)","published_at":"2018-04-16T20:24:58.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants issued pursuant to the Subscription Agreement (the \"Stock Authorization\"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the \"Authorization Date\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the \"Expiration Date\"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years."}],"balance_after":125000,"derivative":{"exercise_price":0.4,"underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-18-024991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024991/doc4.xml","form_type":"4"}},{"id":3963504,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock A Warrants (Right to Buy)","published_at":"2018-04-16T20:24:58.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."}],"balance_after":125000,"derivative":{"exercise_price":0.4,"exercise_date":"2018-04-12","expiration_date":"2020-04-12","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-18-024991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024991/doc4.xml","form_type":"4"}},{"id":3963503,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-16T20:24:58.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."}],"balance_after":280000,"source":{"system":"sec-edgar","filing":"0001209191-18-024991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024991/doc4.xml","form_type":"4"}},{"id":3963502,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165549,"kind":"person","name":"Schwieterman William D","position":1,"cik":"0001403961","reported_name":"Schwieterman William D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock B Warrant (Right to Buy)","published_at":"2018-04-16T20:23:45.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":312500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 2.5 Units purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants (the \"Stock Authorization\"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the \"Authorization Date\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the \"Expiration Date\"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years."}],"balance_after":312500,"derivative":{"exercise_price":0.4,"underlying":"Common Stock","underlying_shares":312500},"source":{"system":"sec-edgar","filing":"0001209191-18-024989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024989/doc4.xml","form_type":"4"}},{"id":3963501,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165549,"kind":"person","name":"Schwieterman William D","position":1,"cik":"0001403961","reported_name":"Schwieterman William D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock A Warrant (Right to Buy)","published_at":"2018-04-16T20:23:45.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":312500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 2.5 Units purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."}],"balance_after":312500,"derivative":{"exercise_price":0.4,"exercise_date":"2018-04-12","expiration_date":"2020-04-12","underlying":"Common Stock","underlying_shares":312500},"source":{"system":"sec-edgar","filing":"0001209191-18-024989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024989/doc4.xml","form_type":"4"}},{"id":3963500,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165549,"kind":"person","name":"Schwieterman William D","position":1,"cik":"0001403961","reported_name":"Schwieterman William D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-04-16T20:23:45.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":625000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 2.5 Units purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."}],"balance_after":625747,"source":{"system":"sec-edgar","filing":"0001209191-18-024989","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024989/doc4.xml","form_type":"4"}},{"id":3963499,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock B Warrant (Right to Buy)","published_at":"2018-04-16T20:22:00.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants (the \"Stock Authorization\"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the \"Authorization Date\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the \"Expiration Date\"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years."}],"balance_after":125000,"derivative":{"exercise_price":0.4,"underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-18-024986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024986/doc4.xml","form_type":"4"}},{"id":3963498,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock A Warrant (Right to Buy)","published_at":"2018-04-16T20:22:00.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."}],"balance_after":125000,"derivative":{"exercise_price":0.4,"exercise_date":"2018-04-12","expiration_date":"2020-04-12","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-18-024986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024986/doc4.xml","form_type":"4"}},{"id":3963497,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-04-16T20:22:00.000Z","date":"2018-04-12","kind":"purchase","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the \"Company\"), dated April 12, 2018 (the \"Subscription Agreement\"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the \"Common Stock\"), (ii) an \"A\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a \"B\" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001209191-18-024986","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118024986/doc4.xml","form_type":"4"}},{"id":4286214,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":75587,"kind":"person","name":"Pedder Simon","position":1,"cik":"0001316736","reported_name":"Pedder Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-13T00:31:50.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":121483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Pedder was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 9, 2018, subject to Dr. Pedder's continued service on the Board of Directors as of such date."}],"balance_after":121483,"derivative":{"exercise_price":0.51,"expiration_date":"2023-06-09","underlying":"Common Stock","underlying_shares":121483},"source":{"system":"sec-edgar","filing":"0001209191-17-039320","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919117039320/doc4.xml","form_type":"4"}},{"id":4286213,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165548,"kind":"person","name":"SANDAGE BOBBY W. JR., PHD.","position":1,"cik":"0001046352","reported_name":"SANDAGE BOBBY W. JR., PHD.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-13T00:30:56.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":121483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 9, 2018, subject to Dr. Sandage's continued service on the Board of Directors as of such date."}],"balance_after":121483,"derivative":{"exercise_price":0.51,"expiration_date":"2023-06-09","underlying":"Common Stock","underlying_shares":121483},"source":{"system":"sec-edgar","filing":"0001209191-17-039319","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919117039319/doc4.xml","form_type":"4"}},{"id":4286212,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-13T00:29:54.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":121483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Reynolds was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 9, 2018, subject to Mr. Reynolds' continued service on the Board of Directors as of such date."}],"balance_after":121483,"derivative":{"exercise_price":0.51,"expiration_date":"2023-06-09","underlying":"Common Stock","underlying_shares":121483},"source":{"system":"sec-edgar","filing":"0001209191-17-039317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919117039317/doc4.xml","form_type":"4"}},{"id":4491433,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165549,"kind":"person","name":"Schwieterman William D","position":1,"cik":"0001403961","reported_name":"Schwieterman William D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-01-13T22:02:38.000Z","date":"2017-01-12","kind":"grant","acquired":true,"shares":550000,"price":0.375,"value":206250.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Schwieterman was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as President and Chief Executive Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options will vest in forty-eight equal monthly installments beginning one month after the grant date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Dr. Schwieterman was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as President and Chief Executive Officer."}],"balance_after":550000,"derivative":{"exercise_price":0.375,"expiration_date":"2027-01-12","underlying":"Common Stock","underlying_shares":550000},"source":{"system":"sec-edgar","filing":"0001209191-17-003704","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919117003704/doc4.xml","form_type":"4"}},{"id":4491432,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165546,"kind":"person","name":"LOAR MATTHEW M","position":1,"cik":"0001236260","reported_name":"LOAR MATTHEW M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-01-13T22:01:58.000Z","date":"2017-01-12","kind":"grant","acquired":true,"shares":350000,"price":0.375,"value":131250.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Loar was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options will vest in forty-eight equal monthly installments beginning one month after the grant date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Mr. Loar was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Financial Officer."}],"balance_after":350000,"derivative":{"exercise_price":0.375,"expiration_date":"2027-01-12","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001209191-17-003702","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919117003702/doc4.xml","form_type":"4"}},{"id":4491431,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165545,"kind":"person","name":"CHAPLIN DAVID","position":1,"cik":"0001167232","reported_name":"CHAPLIN DAVID","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-01-13T22:01:15.000Z","date":"2017-01-12","kind":"grant","acquired":true,"shares":262500,"price":0.375,"value":98437.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Chaplin was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Scientific Officer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options will vest in forty-eight equal monthly installments beginning one month after the grant date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Dr. Chaplin was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Scientific Officer."}],"balance_after":262500,"derivative":{"exercise_price":0.375,"expiration_date":"2027-01-12","underlying":"Common Stock","underlying_shares":262500},"source":{"system":"sec-edgar","filing":"0001209191-17-003700","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919117003700/doc4.xml","form_type":"4"}},{"id":4515883,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $.01 par value per share","published_at":"2016-12-20T21:15:44.000Z","date":"2016-12-16","kind":"purchase","acquired":true,"shares":9950,"price":0.355,"value":3532.25,"ownership":{"direct":true},"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-16-156108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919116156108/doc4.xml","form_type":"4"}},{"id":4515882,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $.01 par value per share","published_at":"2016-12-20T21:15:44.000Z","date":"2016-12-16","kind":"purchase","acquired":true,"shares":7350,"price":0.35,"value":2572.5,"ownership":{"direct":true},"balance_after":20050,"source":{"system":"sec-edgar","filing":"0001209191-16-156108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919116156108/doc4.xml","form_type":"4"}},{"id":4515881,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $.01 par value per share","published_at":"2016-12-20T21:15:44.000Z","date":"2016-12-16","kind":"purchase","acquired":true,"shares":12700,"price":0.34,"value":4318.0,"ownership":{"direct":true},"balance_after":12700,"source":{"system":"sec-edgar","filing":"0001209191-16-156108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919116156108/doc4.xml","form_type":"4"}},{"id":4573634,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165548,"kind":"person","name":"SANDAGE BOBBY W. JR., PHD.","position":1,"cik":"0001046352","reported_name":"SANDAGE BOBBY W PHD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-27T20:28:58.000Z","date":"2016-10-25","kind":"grant","acquired":true,"shares":135612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"Stock Options\"), in connection with his appointment to the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in three equal annual installments on the first, second and third anniversary of the date of grant, subject to Dr. Sandage's continued service on the Board of Directors as of such date."}],"balance_after":135612,"derivative":{"exercise_price":0.58,"expiration_date":"2022-10-25","underlying":"Common Stock","underlying_shares":135612},"source":{"system":"sec-edgar","filing":"0001209191-16-147151","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919116147151/doc4.xml","form_type":"4"}},{"id":4573635,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165547,"kind":"person","name":"Reynolds Donald Rogers","position":1,"cik":"0001687930","reported_name":"Reynolds Donald Rogers","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-27T20:24:03.000Z","date":"2016-10-25","kind":"grant","acquired":true,"shares":135612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Reynolds was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"Stock Options\"), in connection with his appointment to the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in three equal annual installments on the first, second and third anniversary of the date of grant, subject to Mr. Reynolds' continued service on the Board of Directors as of such date."}],"balance_after":135612,"derivative":{"exercise_price":0.58,"expiration_date":"2022-10-25","underlying":"Common Stock","underlying_shares":135612},"source":{"system":"sec-edgar","filing":"0001209191-16-147149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919116147149/doc4.xml","form_type":"4"}}]}